A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Following Administration of MK7009 in Hepatitis C Infected Patients.

Trial Profile

A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Following Administration of MK7009 in Hepatitis C Infected Patients.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Vaniprevir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 28 Sep 2014 The Endpoint assessment timeframe has changed from (0-24hrs) to (148 days) according to ClinicalTrails.gov.
    • 08 Feb 2012 Actual patient number is 3 according to ClinicalTrials.gov.
    • 05 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top